Geroprotective Precision Medicine Strategies in PWH That Use Alcohol
Louisiana State University Health Sciences Center in New Orleans
Summary
People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.
Description
This is a randomized, double-blind, controlled, crossover mechanistic clinical trial in people with HIV who have recent alcohol use. Participants are randomized to receive either Limosilactobacillus reuteri probiotic or blueberry extract first for 4 weeks, followed by a 6-week washout period, then crossover to the alternate intervention for 4 weeks. Each participant receives both interventions. Both interventions are generally recognized as safe (GRAS) dietary supplements and are not intended to diagnose, treat, cure, or prevent disease. This study is not conducted under an Investigational Ne…
Eligibility
- Age range
- 40+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥40 years * People with HIV * Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG) Exclusion Criteria: * Probiotic use in past 3 months * Recent antibiotics or immunosuppressives * Allergy to study products * Pregnancy or breastfeeding * Inability to comply
Interventions
- Dietary SupplementLimosilactobacillus reuteri
Administered as 6 capsules daily (3 twice daily) for 4 weeks. Each daily dose contains 1×10\^10 CFU total in a 1:1 ratio of two strains. This is a GRAS dietary supplement and not an FDA-regulated investigational product.
- Dietary SupplementBlueberry extract
Administered as 6 capsules daily (3 twice daily) for 4 weeks, providing 500 mg anthocyanins per day. This is a GRAS dietary supplement and not an FDA-regulated investigational product.
Location
- LSU HealthNew Orleans, Louisiana